Retrophin Inc (RTRX)

19.56
0.05 0.26
NASDAQ : Health Care
Prev Close 19.51
Open 19.46
Day Low/High 19.36 / 19.71
52 Wk Low/High 11.60 / 37.04
Volume 241.28K
Avg Volume 438.00K
Exchange NASDAQ
Shares Outstanding 37.73M
Market Cap 728.61M
EPS 3.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

RTRX January 2019 Options Begin Trading

RTRX January 2019 Options Begin Trading

Investors in Retrophin, Inc. saw new options begin trading today, for the January 2019 expiration.

Retrophin Reaches Agreement With FDA Under Special Protocol Assessment For Pivotal Trial Evaluating RE-024 In PKAN

Retrophin Reaches Agreement With FDA Under Special Protocol Assessment For Pivotal Trial Evaluating RE-024 In PKAN

Phase 3 trial expected to initiate before year-end 2016

Retrophin Becomes Oversold (RTRX)

Retrophin Becomes Oversold (RTRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BTX, CARB, GHC, IPHS, PLPC, PXD, RP Downgrades: AIQ, EGL, ESIO, ETSY, MTRX, PKOH, RTRX, USAK Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Health Care Stocks Bound for Declines After 2016 Election

Health Care Stocks Bound for Declines After 2016 Election

Stocks in the health care sector are vulnerable to declines following the 2016 presidential election, according to S&P analyst Scott Kessler.

Retrophin Announces Positive Results for Kidney Disease Drug

Retrophin Announces Positive Results for Kidney Disease Drug

Shares of Retrophin surged Wednesday after announcing positive results for its drug that treats a rare kidney disease.

Retrophin (RTRX) Stock Price Target Upped at Leerink on Kidney Drug Trial

Retrophin (RTRX) Stock Price Target Upped at Leerink on Kidney Drug Trial

Leerink raised its price target on Retrophin's (RTRX) stock Wednesday after the company's sparsentan drug that treats a rare kidney disease saw positive results in a phase II clinical trial.

Retrophin (With Help From Martin Shkreli) Advances Drug for Rare Kidney Disease

Retrophin (With Help From Martin Shkreli) Advances Drug for Rare Kidney Disease

Retrophin announced positive results from a study in which patients with a rare kidney disease responded to treatment with its experimental drug sparsentan.

Big Pharma's Punishment in Court of Public Opinion

Big Pharma's Punishment in Court of Public Opinion

Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.

Retrophin (RTRX) Weak On High Volume Today

Retrophin (RTRX) Weak On High Volume Today

Trade-Ideas LLC identified Retrophin (RTRX) as a weak on high relative volume candidate

Retrophin Announces New Data From Physician-Initiated Treatment With RE-024 At The 20th International Congress Of Parkinson's Disease And Movement Disorders

Retrophin Announces New Data From Physician-Initiated Treatment With RE-024 At The 20th International Congress Of Parkinson's Disease And Movement Disorders

RE-024 treatment associated with clinically meaningful improvements in two PKAN patients

First Week of August 19th Options Trading For Retrophin (RTRX)

First Week of August 19th Options Trading For Retrophin (RTRX)

Investors in Retrophin, Inc. saw new options begin trading this week, for the August 19th expiration.

Retrophin (RTRX) Is Today's Strong On High Volume Stock

Retrophin (RTRX) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Retrophin (RTRX) as a strong on high relative volume candidate